{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:38:16Z","timestamp":1794879496632,"version":"4.9.1"},"reference-count":35,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"JSPS","award":["16K19552"],"award-info":[{"award-number":["16K19552"]}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,4,13]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pituitary dysfunction is a life-threatening immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). To date, it is not possible to identify patients who may develop pituitary irAEs prior to ICI treatment. The aim of this study was to characterize the predisposition for ICI-induced pituitary irAEs by analyzing anti-pituitary antibodies (APAs) and human leukocyte antigens (HLAs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this case\u2013control study, APAs and HLA alleles were analyzed in 62 patients (17 who developed ICI-induced isolated adrenocorticotropic hormone deficiency (ICI-IAD), 5 who developed ICI-induced hypophysitis (ICI-H) and 40 who did not develop pituitary irAEs) treated with ICIs between November 2, 2015, and March 31, 2020, at Nagoya University Hospital. The main outcome measures in this study were the association between the development of pituitary irAEs with APAs at baseline and after treatment and HLA alleles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven of 17 (64.7%) patients who developed ICI-IAD had APAs at baseline, whereas APAs were positive only in 1 of 40 (2.5%) control patients. Although APAs were negative at baseline in all patients who developed ICI-H, they had become positive before the onset of ICI-H in 3 of 4 patients several weeks after ipilimumab administration. At the onset of ICI-IAD and ICI-H, APAs were positive in 15 of 17 (88.2%) and 4 of 5 (80%) patients, respectively. The prevalence of HLA-Cw12, HLA-DR15, HLA-DQ7, and HLA-DPw9 was significantly higher in patients with ICI-IAD, whereas that of HLA-Cw12 and HLA-DR15 was significantly higher in patients with ICI-H than in controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study showed distinct and overlapped patterns of APAs and HLA alleles between ICI-IAD and ICI-H. Our findings also showed that positive APAs at baseline and after treatment, together with susceptible HLA alleles, could become predictive biomarkers for ICI-IAD and ICI-H, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>UMIN000019024.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-002493","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T09:05:13Z","timestamp":1621415113000},"page":"e002493","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":80,"title":["Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors"],"prefix":"10.1136","volume":"9","author":[{"given":"Tomoko","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-0337","authenticated-orcid":false,"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Okuji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Onoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"},{"name":"Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"},{"name":"Division of Cancer Immunology, Research Institute\/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2025100304321879000_9.5.e002493.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2025100304321879000_9.5.e002493.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0442-6"},{"key":"2025100304321879000_9.5.e002493.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.09.002"},{"key":"2025100304321879000_9.5.e002493.4","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100304321879000_9.5.e002493.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025100304321879000_9.5.e002493.6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2025100304321879000_9.5.e002493.7","first-page":"4229","article-title":"Adrenal insufficiency related to Anti-Programmed death-1 therapy","volume":"37","author":"Ariyasu","year":"2017","journal-title":"Anticancer Res"},{"key":"2025100304321879000_9.5.e002493.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020"},{"key":"2025100304321879000_9.5.e002493.9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100304321879000_9.5.e002493.10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1507\/endocrj.EJ20-0436","article-title":"Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands","volume":"67","author":"Iwama","year":"2020","journal-title":"Endocr J"},{"key":"2025100304321879000_9.5.e002493.11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1210\/jc.2014-1049","article-title":"Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases","volume":"99","author":"Ricciuti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100304321879000_9.5.e002493.12","doi-asserted-by":"crossref","unstructured":"Lupi I , Brancatella A , Cosottini M , et al . Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep 2019;2019.doi:10.1530\/EDM-19-0102","DOI":"10.1530\/EDM-19-0102"},{"key":"2025100304321879000_9.5.e002493.13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti\u2010PD\u20101 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol"},{"key":"2025100304321879000_9.5.e002493.14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100304321879000_9.5.e002493.15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-Thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"key":"2025100304321879000_9.5.e002493.16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"2025100304321879000_9.5.e002493.17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"2025100304321879000_9.5.e002493.18","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0242"},{"key":"2025100304321879000_9.5.e002493.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100304321879000_9.5.e002493.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2411"},{"key":"2025100304321879000_9.5.e002493.21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1440-1819.1998.00423.x","article-title":"Hla DR2 and DQ1 frequency among narcoleptic patients in Hong Kong Chinese","volume":"52","author":"Wing","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"key":"2025100304321879000_9.5.e002493.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025100304321879000_9.5.e002493.23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800"},{"key":"2025100304321879000_9.5.e002493.24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-2-200"},{"key":"2025100304321879000_9.5.e002493.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1980.00330200119034"},{"key":"2025100304321879000_9.5.e002493.26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000433-199706000-00020","article-title":"Isolated adrenocorticotropic hormone deficiency: an autopsy case of adrenal crisis","volume":"18","author":"Kubo","year":"1997","journal-title":"Am J Forensic Med Pathol"},{"key":"2025100304321879000_9.5.e002493.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1533209100"},{"key":"2025100304321879000_9.5.e002493.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0338-8"},{"key":"2025100304321879000_9.5.e002493.29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11102-016-0780-8","article-title":"Anti-pituitary antibodies against corticotrophs in IgG4-related hypophysitis","volume":"20","author":"Iwata","year":"2017","journal-title":"Pituitary"},{"key":"2025100304321879000_9.5.e002493.30","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1210\/jc.2014-4209","article-title":"Rabphilin-3A as a targeted autoantigen in lymphocytic Infundibulo-neurohypophysitis","volume":"100","author":"Iwama","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100304321879000_9.5.e002493.31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03347415","article-title":"Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies","volume":"30","author":"Bensing","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"2025100304321879000_9.5.e002493.32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"2025100304321879000_9.5.e002493.33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1399-0039.1997.tb02780.x","article-title":"Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma","volume":"49","author":"Kageshila","year":"1997","journal-title":"Tissue Antigens"},{"key":"2025100304321879000_9.5.e002493.34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1507\/endocrj.EJ19-0569","article-title":"Diagnosis and treatment of autoimmune and IgG4-related hypophysitis: clinical guidelines of the Japan endocrine Society","volume":"67","author":"Takagi","year":"2020","journal-title":"Endocr J"},{"key":"2025100304321879000_9.5.e002493.35","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.2015-2702","article-title":"Hla markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in differential diagnosis","volume":"100","author":"Heaney","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:32:29Z","timestamp":1759491149000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jitc-2021-002493"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002493","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}